Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

HER2-targeted CAR-T immunotherapy

DRUG CLASS:

HER2-targeted CAR-T immunotherapy

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

HER-2 YVMA	Lung Cancer	HER-2 YVMA	Lung Cancer	HER2-targeted CAR-T immunotherapy + poziotinib Sensitive: C2 – Inclusion Criteria HER2-targeted CAR-T immunotherapy + poziotinib Sensitive : C2	HER2-targeted CAR-T immunotherapy + poziotinib Sensitive: C2 – Inclusion Criteria HER2-targeted CAR-T immunotherapy + poziotinib Sensitive : C2
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	HER2-targeted CAR-T immunotherapy Sensitive: D – Preclinical HER2-targeted CAR-T immunotherapy Sensitive : D	HER2-targeted CAR-T immunotherapy Sensitive: D – Preclinical HER2-targeted CAR-T immunotherapy Sensitive : D
HER-2 positive	Colorectal Cancer	HER-2 positive	Colorectal Cancer	HER2-targeted CAR-T immunotherapy Sensitive: D – Preclinical HER2-targeted CAR-T immunotherapy Sensitive : D	HER2-targeted CAR-T immunotherapy Sensitive: D – Preclinical HER2-targeted CAR-T immunotherapy Sensitive : D